内镜下金属支架置入治疗恶性输入袢梗阻的实用性
该单中心回顾性研究纳入2008年1月至2018年12月间11例恶性输入袢梗阻(mALO)患者,评估内镜下金属支架置入(EMSP)的技术成功率、不良事件、临床疗效及预后。结果显示13次操作中12次成功,无不良事件发生,成功置入者临床疗效高,EMSP后中位生存时间为118天。
要点
- EMSP在晚期恶性肿瘤一般状况差的mALO患者中技术成功率高且安全。
- 成功置入EMSP者临床疗效高,mALO复发率低。
- EMSP后中位生存时间为118天,多数患者死于原发病。
核心结论
- 对于因晚期恶性肿瘤一般状况差的mALO患者,EMSP成功率高、可安全施行且临床疗效高。
- EMSP后mALO复发率低。
研究设计与样本
- 单中心回顾性分析,纳入2008年1月至2018年12月间接受EMSP的11例mALO患者。
- 评估项目包括患者特征、EMSP技术成功与不良事件、临床疗效及EMSP后结局。
主要发现
- 手术方式与重建方法:远端胃切除术加Billroth II重建3例,胰十二指肠切除术加改良Child重建7例,胆管空肠吻合加Roux-en-Y重建1例。
- mALO原因:腹膜播散6例,局部复发3例,淋巴结转移1例,输入袢受侵1例。
- 11例患者共尝试13次EMSP,13次中12次成功,无不良事件发生。
- EMSP成功者临床疗效高,EMSP后中位生存时间为118天。
- 10例死于原发病,1例在EMSP失败后死于不可控制的胆管炎;死于原发病的10例中2例mALO复发并重复EMSP。
临床怎么用
- 对于晚期恶性肿瘤一般状况差、手术和经皮肝穿刺治疗困难的mALO患者,可考虑EMSP。
- EMSP成功置入后临床疗效高,且mALO复发率低。
局限性
- 回顾性研究,样本量仅11例。
- 单中心经验,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Malignant afferent loop obstruction (mALO) can cause cholangitis, pancreatitis, and perforation due to blind loop dilatation. However, peritoneal dissemination, lymph node metastasis, and recurrence of the tumor are the main causes of mALO, and most cases are in the advanced stage with thoracicoabdominal fluid retention, for which surgery and percutaneous transhepatic treatment are challenging. At our hospital, endoscopic metal stent placement (EMSP) has been applied for such mALO. We retrospectively investigated the usefulness of EMSP for mALO. METHODS: We conducted a retrospective analysis of 11 mALO patients with EMSP between January 2008 and December 2018. The following items were evaluated: the characteristics of patients, technical success and adverse events of EMSP, clinical efficacy, and outcome after EMSP. RESULTS: The surgical procedures and reconstruction methods were distal gastrectomy with Billroth II reconstruction for 3 patients, pancreaticoduodenectomy with modified-Child reconstruction for 7, choledochojejunostomy with Roux-en-Y reconstruction for 1. The cause of mALO was peritoneal dissemination for 6 patients, local recurrence for 3, lymph node metastasis for 1, and afferent loop invasion for 1. EMSP was attempted in 13 sessions for 11 patients, and successful in 12 of 13 sessions. There were no adverse events. The clinical efficacy was high in successful EMSP. The median survival time after EMSP was 118 days. Ten patients died of primary disease and one patient died of uncontrollable cholangitis after the failure of EMSP. mALO recurred and EMSP was repeated for 2 of 10 patients who died of primary disease. CONCLUSIONS: The success rate of EMSP for mALO was high in patients with poor general conditions due to advanced-stage malignant tumors and it was able to be safely performed, suggesting its high clinical efficacy. The incidence of mALO recurrence after EMSP was low.
引用
- Kida A, Kido H, Matsuo T, et al. Usefulness of endoscopic metal stent placement for malignant afferent loop obstruction. Surg Endosc. 2019. PMID: 31338663. doi:10.1007/s00464-019-06991-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。